Skip to main content
Journal cover image

Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Publication ,  Journal Article
Mehta, R; Cai, X; Lee, J; Xie, D; Wang, X; Scialla, J; Anderson, AH; Taliercio, J; Dobre, M; Chen, J; Fischer, M; Leonard, M; Lash, J ...
Published in: Am J Kidney Dis
June 2020

RATIONALE & OBJECTIVE: Studies using a single measurement of fibroblast growth factor 23 (FGF-23) suggest that elevated FGF-23 levels are associated with increased risk for requirement for kidney replacement therapy (KRT) in patients with chronic kidney disease. However, the data do not account for changes in FGF-23 levels as kidney disease progresses. STUDY DESIGN: Case-cohort study. SETTING & PARTICIPANTS: To evaluate the association between serial FGF-23 levels and risk for requiring KRT, our primary analysis included 1,597 individuals in the Chronic Renal Insufficiency Cohort Study who had up to 5 annual measurements of carboxy-terminal FGF-23. There were 1,135 randomly selected individuals, of whom 266 initiated KRT, and 462 individuals who initiated KRT outside the random subcohort. EXPOSURE: Serial FGF-23 measurements and FGF-23 trajectory group membership. OUTCOMES: Incident KRT. ANALYTICAL APPROACH: To handle time-dependent confounding, our primary analysis of time-updated FGF-23 levels used time-varying inverse probability weighting in a discrete time failure model. To compare our results with prior data, we used baseline and time-updated FGF-23 values in weighted Cox regression models. To examine the association of FGF-23 trajectory subgroups with risk for incident KRT, we used weighted Cox models with FGF-23 trajectory groups derived from group-based trajectory modeling as the exposure. RESULTS: In our primary analysis, the HR for the KRT outcome per 1 SD increase in the mean of natural log-transformed (ln)FGF-23 in the past was 1.94 (95% CI, 1.51-2.49). In weighted Cox models using baseline and time-updated values, elevated FGF-23 level was associated with increased risk for incident KRT (HRs per 1 SD ln[FGF-23] of 1.18 [95% CI, 1.02-1.37] for baseline and 1.66 [95% CI, 1.49-1.86] for time-updated). Membership in the slowly and rapidly increasing FGF-23 trajectory groups was associated with ∼3- and ∼21-fold higher risk for incident KRT compared to membership in the stable FGF-23 trajectory group. LIMITATIONS: Residual confounding and lack of intact FGF-23 values. CONCLUSIONS: Increasing FGF-23 levels are independently associated with increased risk for incident KRT.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Kidney Dis

DOI

EISSN

1523-6838

Publication Date

June 2020

Volume

75

Issue

6

Start / End Page

908 / 918

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Risk Factors
  • Risk Assessment
  • Renal Replacement Therapy
  • Renal Insufficiency, Chronic
  • Proportional Hazards Models
  • Middle Aged
  • Male
  • Kidney Transplantation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mehta, R., Cai, X., Lee, J., Xie, D., Wang, X., Scialla, J., … CRIC Study Investigators, . (2020). Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis, 75(6), 908–918. https://doi.org/10.1053/j.ajkd.2019.09.009
Mehta, Rupal, Xuan Cai, Jungwha Lee, Dawei Xie, Xue Wang, Julia Scialla, Amanda H. Anderson, et al. “Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study.Am J Kidney Dis 75, no. 6 (June 2020): 908–18. https://doi.org/10.1053/j.ajkd.2019.09.009.
Mehta, Rupal, et al. “Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study.Am J Kidney Dis, vol. 75, no. 6, June 2020, pp. 908–18. Pubmed, doi:10.1053/j.ajkd.2019.09.009.
Mehta R, Cai X, Lee J, Xie D, Wang X, Scialla J, Anderson AH, Taliercio J, Dobre M, Chen J, Fischer M, Leonard M, Lash J, Hsu C-Y, de Boer IH, Feldman HI, Wolf M, Isakova T, CRIC Study Investigators. Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2020 Jun;75(6):908–918.
Journal cover image

Published In

Am J Kidney Dis

DOI

EISSN

1523-6838

Publication Date

June 2020

Volume

75

Issue

6

Start / End Page

908 / 918

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Risk Factors
  • Risk Assessment
  • Renal Replacement Therapy
  • Renal Insufficiency, Chronic
  • Proportional Hazards Models
  • Middle Aged
  • Male
  • Kidney Transplantation